Jamunarani Veeraraghavan
Overview
Explore the profile of Jamunarani Veeraraghavan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
936
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdulkareem N, Bhat R, Castillo M, Jung S, Vasaikar S, Nanda S, et al.
Br J Pharmacol
. 2025 Feb;
PMID: 39965212
Background And Purpose: We and others have previously shown that ADGRF1, an adhesion G protein-coupled receptor, is overexpressed and associated with poor survival in many cancers, including human epidermal growth...
2.
Veeraraghavan J, De Angelis C, Gutierrez C, Liao F, Sabotta C, Rimawi M, et al.
Adv Exp Med Biol
. 2025 Jan;
1464():495-525.
PMID: 39821040
HER2-positive (+) breast cancer is an aggressive disease with poor prognosis, a narrative that changed drastically with the advent and approval of trastuzumab, the first humanized monoclonal antibody targeting HER2....
3.
Fu X, Pereira R, Liu C, De Angelis C, Shea M, Nanda S, et al.
Cell Rep
. 2023 Jul;
42(8):112821.
PMID: 37467106
Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers. However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1)...
4.
Veeraraghavan J, Gutierrez C, De Angelis C, Davis R, Wang T, Pascual T, et al.
Clin Cancer Res
. 2023 May;
29(16):3101-3109.
PMID: 37195235
Purpose: Clinical trials reported 25% to 30% pathologic complete response (pCR) rates in HER2+ patients with breast cancer treated with anti-HER2 therapies without chemotherapy. We hypothesize that a multiparameter classifier...
5.
De Angelis C, Fu X, Cataldo M, Nardone A, Pereira R, Veeraraghavan J, et al.
Clin Cancer Res
. 2021 Sep;
27(17):4939.
PMID: 34470810
No abstract available.
6.
Veeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea M, et al.
NPJ Breast Cancer
. 2021 May;
7(1):63.
PMID: 34045483
Lapatinib (L) plus trastuzumab (T), with endocrine therapy for estrogen receptor (ER)+ tumors, but without chemotherapy, yielded meaningful response in HER2+ breast cancer (BC) neoadjuvant trials. The irreversible/pan-HER inhibitor neratinib...
7.
Wang X, Veeraraghavan J, Liu C, Cao X, Qin L, Kim J, et al.
Clin Cancer Res
. 2021 Feb;
27(9):2648-2662.
PMID: 33542078
Purpose: Endocrine resistance remains a major clinical challenge in estrogen receptor (ER)-positive breast cancer. Despite the encouraging results from clinical trials for the drugs targeting known survival signaling, relapse is...
8.
De Angelis C, Fu X, Cataldo M, Nardone A, Pereira R, Veeraraghavan J, et al.
Clin Cancer Res
. 2021 Feb;
27(17):4870-4882.
PMID: 33536276
Purpose: Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) are highly effective against estrogen receptor-positive (ER)/HER2 breast cancer; however, intrinsic and acquired resistance is common. Elucidating the molecular features of...
9.
Liu C, Veeraraghavan J, Tan Y, Kim J, Wang X, Loo S, et al.
Clin Cancer Res
. 2020 Nov;
27(3):785-798.
PMID: 33172895
Purpose: Luminal B breast tumors are more aggressive estrogen receptor-positive (ER) breast cancers characterized by aggressive clinical behavior and a high risk of metastatic dissemination. The underlying pathologic molecular events...
10.
Li L, Lin L, Veeraraghavan J, Hu Y, Wang X, Lee S, et al.
Breast Cancer Res
. 2020 Aug;
22(1):84.
PMID: 32771039
Background: Endocrine therapy is the most common treatment for estrogen receptor (ER)-positive breast cancer, but its effectiveness is limited by high rates of primary and acquired resistance. There are likely...